Bariatric volumes down 34.1% while GLP-1 use rose 140%: the service line is moving

A 2026 JAMA Surgery analysis found bariatric surgery volumes fell 34.1% between 2022 and 2024 while GLP-1 use rose more than 140% over the same stretch ^[1]. For anyone running a hospital service line, that is not a pharmaceutical story: it is a high-margin surgical franchise losing roughly a third of its case volume in two years, with the money reappearing on somebody else's pharmacy benefit.

A Wells Fargo Industry Insights report co-authored by Robin Wenzel, who heads the unit, and John Teasley, a market executive in the bank's healthcare commercial banking group, calls that pairing a direct substitution effect ^[2]. Wenzel told Fortune the drugs have shifted obesity treatment "upstream," away from late-stage interventions such as gastric bypass and orthopedic surgery and toward proactive weight management, and described the change as "a game-changer" ^[3]. Roughly 40% of American adults live with obesity, which is the size of the pool being rerouted ^[4].

Bariatric surgery is the visible casualty. The larger exposure is cardiology: the SELECT trial found semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults without diabetes, a result Wenzel called "an eye-opener" given cardiology's status as one of the most lucrative lines of business in healthcare ^[5]. Evidence is also accumulating in adjacent categories. A Washington University School of Medicine study published in The BMJ in March associated GLP-1 use with an 18% lower risk of alcohol use disorder, with similar reductions across other major addiction categories ^[6].

Capital has already repriced. Obesity therapies now account for about 25% of pharma's forecast late-stage pipeline value, up from 1% in 2022, passing oncology for the first time in 16 years of Deloitte's tracking ^[7]. That is a 25-fold increase in share in roughly three years ^[8]. Wegovy and Ozempic carry list prices as high as $1,000 to $1,300 a month, according to Wenzel, and both remain under patent, which limits competition ^[9]. At list, that is $12,000 to $15,600 per patient per year, indefinitely, because the therapy is chronic ^[10]. Wenzel and Wells Fargo economist Michael Swanson both compare the drugs to statins on that point ^[11].

Which is where the substitution stops being clean. The Congressional Budget Office estimates that authorizing Medicare to cover anti-obesity medications broadly would add about $35 billion to federal spending between 2026 and 2034, with near-term costs of roughly $5,600 per user in 2026 against offsetting health savings of about $50 per user that year ^[12]. That is a 112-to-1 gap in the first year ^[13]. Wenzel's own summary: "This is something that doesn't necessarily pencil out on an annual basis" ^[14]. She is equally direct that coverage under Medicare, Medicaid, or commercial insurance does not always include GLP-1s for weight loss, and that affordability remains the industry's unresolved problem ^[15]. Federal health agencies now classify obesity as a chronic disease shaped by genetics, environment, and food systems ^[16] - a designation that raises the awkwardness of a treatment gated by formulary.

The operating consequence is a two-tier patient population: insured patients treated upstream with drugs, uninsured or excluded patients arriving later and sicker, at surgical volumes too low to sustain the programs built to receive them.

Watch payer formulary decisions on weight-loss indications, and watch whether bariatric and metabolic programs consolidate or convert to medical weight management. Patent expiry timing on the two lead drugs is the variable that changes the arithmetic ^[9].